标题
Harnessing cytokines and chemokines for cancer therapy
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-01-07
DOI
10.1038/s41571-021-00588-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future
- (2021) Geert R D'Haens et al. GUT
- Therapeutic Strategies for Targeting IL-1 in Cancer
- (2021) Adrian Gottschlich et al. Cancers
- Key chemokines direct migration of immune cells in solid tumors
- (2021) Karan Kohli et al. CANCER GENE THERAPY
- Intratumoral Plasmid IL12 Expands CD8+ T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
- (2021) Melinda L. Telli et al. CLINICAL CANCER RESEARCH
- Pegilodecakin as monotherapy or in combination with anti‐PD ‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma ( RCC ): Final results of cohorts A, G, H, and I of IVY Phase I study
- (2021) Nizar M. Tannir et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
- (2021) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients.
- (2021) Karim Chamie et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer
- (2021) Owen Heath et al. Cancer Immunology Research
- Targeting the NLRP3 Inflammasome as a New Therapeutic Option for Overcoming Cancer
- (2021) Sonia Missiroli et al. Cancers
- Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy
- (2021) Pedro Bule et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes
- (2021) Paul B. Chapman JOURNAL OF CLINICAL ONCOLOGY
- Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).
- (2021) John M. Wrangle et al. JOURNAL OF CLINICAL ONCOLOGY
- ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.
- (2021) Valentina Boni et al. JOURNAL OF CLINICAL ONCOLOGY
- Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
- (2021) Omid Hamid et al. JOURNAL OF CLINICAL ONCOLOGY
- The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
- (2021) Margherita Turinetto et al. Frontiers in Oncology
- A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion
- (2021) Beatrice Malacrida et al. iScience
- Clinical significance of chemokine receptor antagonists
- (2020) Miao Miao et al. Expert Opinion on Drug Metabolism & Toxicology
- First-in-human phase I study of intraperitoneally administered interferon-activated autologous monocytes in platinum-resistant or refractory ovarian cancer.
- (2020) Christopher Browning Cole et al. JOURNAL OF CLINICAL ONCOLOGY
- Myc instructs and maintains pancreatic adenocarcinoma phenotype
- (2020) Nicole M Sodir et al. Cancer Discovery
- Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment
- (2020) Eleni Maniati et al. Cell Reports
- Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
- (2020) Hanne Lind et al. Journal for ImmunoTherapy of Cancer
- Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
- (2020) Liuxue Sheng et al. BIOMEDICINE & PHARMACOTHERAPY
- Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
- (2020) Alain P. Algazi et al. CLINICAL CANCER RESEARCH
- Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer
- (2020) Yoon-Koo Kang et al. CLINICAL CANCER RESEARCH
- Rationale for IL-15 superagonists in cancer immunotherapy
- (2020) Karin M. Knudson et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
- (2020) Georg Martin Haag et al. JOURNAL OF CLINICAL ONCOLOGY
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
- (2020) Bruno Bockorny et al. NATURE MEDICINE
- Translating IL-6 biology into effective treatments
- (2020) Ernest H. Choy et al. Nature Reviews Rheumatology
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
- (2020) Brooke Benner et al. Drug Design Development and Therapy
- IL-15 in the Combination Immunotherapy of Cancer
- (2020) Thomas A. Waldmann et al. Frontiers in Immunology
- ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy
- (2020) Jared E Lopes et al. Journal for ImmunoTherapy of Cancer
- Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
- (2020) Changhoon Yoo et al. Journal for ImmunoTherapy of Cancer
- Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
- (2020) Dmitriy Zamarin et al. CLINICAL CANCER RESEARCH
- TGFβ biology in cancer progression and immunotherapy
- (2020) Rik Derynck et al. Nature Reviews Clinical Oncology
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
- (2020) Byoung Chul Cho et al. Journal for ImmunoTherapy of Cancer
- The CCL5/CCR5 Axis in Cancer Progression
- (2020) Donatella Aldinucci et al. Cancers
- Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
- (2020) Joan How et al. Cancers
- Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
- (2020) Paolo Strati et al. Blood Advances
- Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
- (2020) Catherine S. Grasso et al. CANCER CELL
- Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- (2020) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression
- (2020) Kristen Fousek et al. PHARMACOLOGY & THERAPEUTICS
- Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis
- (2020) Jun‐Lin Lu et al. Cancer Medicine
- Localized Interleukin-12 for Cancer Immunotherapy
- (2020) Khue G. Nguyen et al. Frontiers in Immunology
- Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
- (2020) Anne Montfort et al. CLINICAL CANCER RESEARCH
- Advances of CCR5 antagonists: From small molecules to macromolecules
- (2020) Baowen Qi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy
- (2020) Ying Yang et al. Cancers
- Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
- (2020) David Spigel et al. Journal of Thoracic Oncology
- Fine-Tuning Cytokine Signals
- (2019) Jian-Xin Lin et al. Annual Review of Immunology
- Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics
- (2019) Karen Autio et al. Current Oncology Reports
- Phase I Study of Emactuzumab Single Agent or in Combination with Paclitaxel in Patients with Advanced/Metastatic Solid Tumors Reveals Depletion of Immunosuppressive M2-like Macrophages
- (2019) C A Gomez-Roca et al. ANNALS OF ONCOLOGY
- The Immunobiology of the Interleukin-12 Family: Room for Discovery
- (2019) Elia D. Tait Wojno et al. IMMUNITY
- Shared and Distinct Functions of Type I and Type III Interferons
- (2019) Helen M. Lazear et al. IMMUNITY
- MEDIPLEX: A phase 1 study of durvalumab (D) combined with pexidartinib (P) in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
- (2019) Philippe Alexandre Cassier et al. JOURNAL OF CLINICAL ONCOLOGY
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
- (2019) Elisabeth Perez-Ruiz et al. NATURE
- A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors
- (2019) Salah-Eddine Bentebibel et al. Cancer Discovery
- Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC)
- (2019) Celeste Lebbe et al. EUROPEAN JOURNAL OF CANCER
- Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
- (2019) Shabnam Shalapour et al. IMMUNITY
- Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma
- (2019) Marcus Noel et al. INVESTIGATIONAL NEW DRUGS
- Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
- (2019) William D Tap et al. LANCET
- Cancer modeling meets human organoid technology
- (2019) David Tuveson et al. SCIENCE
- Leukocyte Adhesion: Reconceptualizing Chemokine Presentation by Glycosaminoglycans
- (2019) Gerard J. Graham et al. TRENDS IN IMMUNOLOGY
- Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
- (2019) Shihong Zhang et al. Cancer Immunology Research
- Tuning the Tumor Myeloid Microenvironment to Fight Cancer
- (2019) Nadine S. Jahchan et al. Frontiers in Immunology
- A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
- (2019) Jeffrey Melson Clarke et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
- (2019) Toshihiko Doi et al. CLINICAL CANCER RESEARCH
- Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial
- (2019) Aung Naing et al. LANCET ONCOLOGY
- Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours?
- (2019) Sumanta Pal et al. LANCET ONCOLOGY
- Modulators of CXCR4 and CXCR7/ACKR3 function
- (2019) Ilze Adlere et al. MOLECULAR PHARMACOLOGY
- Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
- (2019) Marijo Bilusic et al. Journal for ImmunoTherapy of Cancer
- Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
- (2019) U Dafni et al. ANNALS OF ONCOLOGY
- Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy
- (2019) Stephen K. Doberstein EXPERT OPINION ON BIOLOGICAL THERAPY
- Biology and therapeutic potential of interleukin-10
- (2019) Margarida Saraiva et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma
- (2019) Genmao Cao et al. MEDICINE
- Flip the coin: IL-7 and IL-7R in health and disease
- (2019) João T. Barata et al. NATURE IMMUNOLOGY
- Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience
- (2019) Martin Oft SEMINARS IN IMMUNOLOGY
- NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis
- (2019) Nour Ershaid et al. Nature Communications
- Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer
- (2019) Thomas A. Waldmann et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies
- (2019) Sara K. Daniel et al. SEMINARS IN CANCER BIOLOGY
- A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors
- (2019) Ezra E. W. Cohen et al. Journal for ImmunoTherapy of Cancer
- Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
- (2019) Anfray et al. Cells
- IL-1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer
- (2018) Te-Chia Wu et al. CANCER RESEARCH
- Phase I and biomarker study of plerixafor and bevacizumab in recurrent high-grade glioma
- (2018) Eudocia Q Lee et al. CLINICAL CANCER RESEARCH
- Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab
- (2018) Brandon W. Higgs et al. CLINICAL CANCER RESEARCH
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Overall survival in a trial of orally administered CCR2 inhibitor CCX872 in locally advanced/metastatic pancreatic cancer: Correlation with blood monocyte counts.
- (2018) David Linehan et al. JOURNAL OF CLINICAL ONCOLOGY
- ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial
- (2018) John M Wrangle et al. LANCET ONCOLOGY
- Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
- (2018) Sonia Pernas et al. LANCET ONCOLOGY
- Interleukin-6 and prostate cancer: Current developments and unsolved questions
- (2018) Zoran Culig et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor
- (2018) Keishi Adachi et al. NATURE BIOTECHNOLOGY
- Targeting the IL-6/JAK/STAT3 signalling axis in cancer
- (2018) Daniel E. Johnson et al. Nature Reviews Clinical Oncology
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity
- (2018) Elise Alspach et al. Cold Spring Harbor Perspectives in Biology
- Pharmacodynamics (PD) and genomic profiling of pts treated with cabiralizumab (cabira) + nivolumab (NIVO) provide evidence of on-target tumor immune modulations and support future clinical applications.
- (2018) Michael Carleton et al. JOURNAL OF CLINICAL ONCOLOGY
- NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT.
- (2018) Adi Diab et al. JOURNAL OF CLINICAL ONCOLOGY
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
- (2018) Youn H Kim et al. LANCET ONCOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure?
- (2018) Hans Carl Hasselbalch et al. Seminars in Immunopathology
- Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study
- (2018) Nicolas Isambert et al. OncoImmunology
- Cytokines in clinical cancer immunotherapy
- (2018) Pedro Berraondo et al. BRITISH JOURNAL OF CANCER
- PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients
- (2018) Aung Naing et al. CANCER CELL
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- FADD at the Crossroads between Cancer and Inflammation
- (2018) Sara Mouasni et al. TRENDS IN IMMUNOLOGY
- Anakinra Therapy for Non-cancer Inflammatory Diseases
- (2018) Giulio Cavalli et al. Frontiers in Pharmacology
- Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
- (2018) Ahmad Tarhini et al. Journal for ImmunoTherapy of Cancer
- A novel anti-cancer L19-interleukin-12 fusion protein with an optimized peptide linker efficiently localizes in vivo at the site of tumors
- (2018) Tiziano Ongaro et al. JOURNAL OF BIOTECHNOLOGY
- Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis
- (2017) Natalie J. Ives et al. EUROPEAN JOURNAL OF CANCER
- Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy
- (2017) Dejan Micic et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer
- (2017) Chiara Berlato et al. JOURNAL OF CLINICAL INVESTIGATION
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis
- (2017) Roger Chou et al. JOURNAL OF UROLOGY
- Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
- (2017) Paul M Ridker et al. LANCET
- A randomized phase II study of LY2510924 and carboplatin/etoposide versus carboplatin/etoposide in extensive‐disease small cell lung cancer
- (2017) Ravi Salgia et al. LUNG CANCER
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-6 Family Cytokines
- (2017) Stefan Rose-John Cold Spring Harbor Perspectives in Biology
- Cytokines in Cancer Immunotherapy
- (2017) Thomas A. Waldmann Cold Spring Harbor Perspectives in Biology
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Oncolytic Viral Therapy for Mesothelioma
- (2017) Daniel F. Pease et al. Frontiers in Oncology
- Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma
- (2016) M. Simonelli et al. ANNALS OF ONCOLOGY
- A phase I study of recombinant (r) vaccinia-CEA(6D)-TRICOM and rFowlpox-CEA(6D)-TRICOM vaccines with GM-CSF and IFN-α-2b in patients with CEA-expressing carcinomas
- (2016) Megan C. Duggan et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model
- (2016) Antonio Sacco et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
- (2016) S. Bo hm et al. CLINICAL CANCER RESEARCH
- Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors
- (2016) Aung Naing et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC)
- (2016) John D. Hainsworth et al. Targeted Oncology
- TGF-β Family Signaling in the Control of Cell Proliferation and Survival
- (2016) Yun Zhang et al. Cold Spring Harbor Perspectives in Biology
- Targeting the CCL2-CCR2 signaling axis in cancer metastasis
- (2016) Su Yin Lim et al. Oncotarget
- A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
- (2016) Andrew S. Brohl et al. Journal for ImmunoTherapy of Cancer
- Interleukin-6 as a Therapeutic Target
- (2015) J.-F. Rossi et al. CLINICAL CANCER RESEARCH
- A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors
- (2015) L. W. Goff et al. CLINICAL CANCER RESEARCH
- Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer
- (2015) Kevin C. Conlon et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
- (2015) Mythili Koneru et al. Journal of Translational Medicine
- Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study
- (2015) Nicholas Butowski et al. NEURO-ONCOLOGY
- The immunocytokine NHS-IL12 as a potential cancer therapeutic
- (2015) Jonathan Fallon et al. Oncotarget
- Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- (2014) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Interleukin 12: still a promising candidate for tumor immunotherapy?
- (2014) Witold Lasek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
- (2014) M. D. Galsky et al. CLINICAL CANCER RESEARCH
- PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial
- (2014) A. Necchi et al. INVESTIGATIONAL NEW DRUGS
- IL-2: The First Effective Immunotherapy for Human Cancer
- (2014) S. A. Rosenberg JOURNAL OF IMMUNOLOGY
- Cancer-related inflammation and treatment effectiveness
- (2014) Connie I Diakos et al. LANCET ONCOLOGY
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial
- (2014) Frits van Rhee et al. LANCET ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
- (2014) John C. Morris et al. PLoS One
- IL-6 and related cytokines as the critical lynchpins between inflammation and cancer
- (2014) Koji Taniguchi et al. SEMINARS IN IMMUNOLOGY
- Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
- (2014) Irene Brana et al. Targeted Oncology
- High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
- (2014) Janice P Dutcher et al. Journal for ImmunoTherapy of Cancer
- Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
- (2014) Roxanne Payne et al. Journal for ImmunoTherapy of Cancer
- Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
- (2013) Wei Liao et al. IMMUNITY
- IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
- (2012) J. Emmerich et al. CANCER RESEARCH
- A review on CXCR4/CXCL12 axis in oncology: No place to hide
- (2012) Urszula M. Domanska et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- Paraneoplastic Thrombocytosis in Ovarian Cancer
- (2012) Rebecca L. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
- (2012) John H. Sampson et al. PLoS One
- Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey
- (2011) B. B. Aggarwal et al. BLOOD
- IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
- (2011) John B. Mumm et al. CANCER CELL
- Interleukin-6 as a Therapeutic Target in Human Ovarian Cancer
- (2011) Jermaine Coward et al. CLINICAL CANCER RESEARCH
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma
- (2011) Ahmad A. Tarhini et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-related inflammation: Common themes and therapeutic opportunities
- (2011) Frances R. Balkwill et al. SEMINARS IN CANCER BIOLOGY
- Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
- (2010) J. F. M. Jacobs et al. CLINICAL CANCER RESEARCH
- Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
- (2009) Andrew J. Rech et al. Annals of the New York Academy of Sciences
- Role of cytokine therapy for Renal Cell Carcinoma in the era of targeted agents
- (2009) Sebastien J. Hotte et al. Current Oncology
- The role of differential expression of human interferon-A genes in antiviral immunity
- (2009) Pierre Génin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
- (2008) E. R. Brown et al. ANNALS OF ONCOLOGY
- Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival
- (2008) David S. Alberts et al. GYNECOLOGIC ONCOLOGY
- Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma
- (2008) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation